The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production. The Life Science business of Merck KGaA, Darmstadt, Germany acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.

“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio”, says Gabriel Baertschi, CEO, Grünenthal. “The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.”

Under the Asset Purchase Agreement, Meitheal Pharmaceuticals acquires North America rights to CONTEPO™, including any results of development and regulatory activities, and all intellectual property (IP) rights, technology, and know-how related to CONTEPO™. In exchange, Nabriva will receive payment upon closing and a royalty on net U.S. sales of CONTEPO™.

Zensar Technologies notes this strategic move strengthens Zensar’s Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.

“We are thrilled to welcome Volpara into the Lunit family. Today, we take a monumental step towards revolutionizing our approach to cancer care. By combining our strengths, we are creating a formidable alliance in the industry, particularly in the US market. This merger enables us to develop and deliver innovative, life-saving solutions that meet critical needs in cancer diagnostics,” said Brandon Suh, CEO of Lunit.